Research Papers:

Prognostic role of extracellular matrix metalloproteinase inducer/CD147 in gastrointestinal cancer: a meta-analysis of related studies

Xiaohui Huang, Weisong Shen, Weisong Shen, Hongqing Xi, Hongqing Xi, Kecheng Zhang, Kecheng Zhang, Jianxin Cui, Jianxin Cui, Bo Wei, Bo Wei, Lin Chen _ and Lin Chen _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:81003-81011. https://doi.org/10.18632/oncotarget.12745

Metrics: PDF 2004 views  |   HTML 1733 views  |   ?  


Xiaohui Huang1,*, Weisong Shen2,*, Hongqing Xi1, Kecheng Zhang1, Jianxin Cui1, Bo Wei1, Lin Chen1

1Department of General Surgery, Chinese People’s Liberation Army General Hospital, Beijing 100853, China

2Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China

*These authors have contributed equally to this work

Correspondence to:

Lin Chen, email: [email protected]

Bo Wei, email: [email protected]

Keywords: gastrointestinal cancer, CD147, prognosis, meta-analysis

Received: June 16, 2016    Accepted: October 03, 2016    Published: October 19, 2016


The prognostic role of Extracellular matrix metalloproteinase inducer (EMMPRIN/ CD147) in gastrointestinal cancer remains controversial. We systematically reviewed the evidence of assessment of CD147 expression in gastrointestinal cancer to help clarify this issue. Pubmed, Embase, Cochrane Library and Web of Science databases were searched to identify eligible studies to evaluate the association of CD147 expression and disease-free and overall survival of gastrointestinal cancer. Hazard ratios (HRs) were pooled to estimate the effect. CD147 overexpression was significantly correlated with poor disease-free survival (HR 2.38, 95% CI 1.43–3.97) and overall survival (HR 1.64, 95% CI 1.25–2.14) of cancer patients. Furthermore, CD147 overexpression was significantly association with TNM stage (TIII/TIV vs TI/TII: OR 3.60, 95% CI 1.85–7.01), the depth of invasion (T3/T4 vs T1/T2: OR 2.04, 95% CI 1.25–3.33), lymph node metastasis (positive vs negative: 2.35, 95% CI 1.14–4.86), distant metastasis (positive vs negative: OR 4.78, 95% CI 1.43–16.00). Our analyses demonstrate that CD147 was effectively predictive of worse prognosis in gastrointestinal cancer. Moreover, Identifying CD147 may help identify new drug targets for cancer therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12745